Publications

2019

Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Trends in opioid prescribing for adolescents and young adults in ambulatory care settings. Pediatrics 2019;143(6):e20181578. PubMed

Bourgeois FT, Graham DA, Kesselheim AS, Randolph AG. Cost implications of escalating intravenous acetaminophen use in children. JAMA Pediatr 2019. PubMed

Hwang TJ, Orenstein L, Kesselheim AS, Bourgeois FT. Completion rate and reporting of mandatory pediatric postmarketing studies under the US Pediatric Research Equity Act. JAMA Pediatr 2019;173(1):68-74. PubMed

Rees CA, Hotez PJ, Monuteaux MC, Niescierenko M, Bourgeois FT. Neglected tropical diseases in children: An assessment of gaps in research prioritization. PLoS Negl Trop Dis 2019;13(1):e0007111. PubMed

Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact of the priority review voucher program on drug development for rare pediatric diseases. Health Aff 2019;38(2):313-319. PubMed

2018

Hwang TJ, Tomasi PA, Bourgeois FT. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: a cohort study. PLOS Medicine 2018;15(3):e1002520. PubMed

Hwang TJ, Tomasi PA, Saint-Raymond A, Bourgeois FT. Availability of paediatric information in European Medicines Agency approvals. Lancet Child and Adolescent Health 2018;2(5):e9. PubMed

Hudgins JD, Bacho MA, Olsen KL, Bourgeois FT. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis. Pharmacoepidemiology and Drug Safety 2018;27(2):161-167. PubMed

Bourgeois FT, Hwang TJ. Improving the study of new medicines for children with rare diseases. JAMA Pediatrics 2018;172(1):7-9. PubMed

2016-7

Bourgeois FT, Hwang TJ. The Pediatric Research Equity Act moves into adolescence. JAMA 2017;317(3):259-260. PubMed

Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics 2016;138(3):e20160223. PubMed

Lebowitz MB, Olson KL, Burns M, Harper MB, Bourgeois F. Drug-drug interactions among hospitalized children receiving chronic antiepileptic drug therapy. Hospital Pediatrics 2016;6(5):282-289. PubMed

2014-5

Bourgeois FT, Olson KL, Poduri A, Mandl KD. Comparison of drug utilization patterns in observational data: antiepileptic drugs in pediatric patients. Paediatric Drugs 2015;17(5):401-410. PubMed

Hwang TJ, Kesselheim AS, Bourgeois FT. Postmarketing trials and pediatric device approvals. Pediatrics 2014;133(5):e1197-1202. PubMed

Hwang TJ, Bourgeois FT. New regulatory paradigms for innovative drugs to treat pediatric diseases. JAMA Pediatrics. 2014;168(10):879-880. PubMed

Bourgeois F, Olson K, Ioannidis J, Mandl K. Association between pediatric clinical trials and global burden of disease. Pediatrics 2014;133(1):78-87. PubMed

Tay KY, Ewald M, Bourgeois F. Use of QT-prolonging medications in US emergency departments, 1995-2009 Pharmacoepidemiology and Drug Safety 2014;23(1):9-17. PubMed

Bourgeois FT, Kim JM, Mandl KD. Premarket safety and efficacy studies for ADHD medications in children. PLoS One. 2014;9(7):e102249. PubMed